(Reuters) - Pfizer Inc, which in May abandoned its $118 billion bid for AstraZeneca Plc, on Tuesday left investors guessing whether it would renew its pursuit of its British rival, but said it was considering other deals.The largest U.S. drugmaker reported higher-than-expected second-quarter revenue,...